Telomere dysfunction and its role in haematological cancer

British Journal of Haematology

Volumn 156, Issue 5, 2012, Pages 573-587

  Jones, Ceri H ^a   Pepper, Chris ^a   Baird, Duncan M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Genome instability; Haematological malignancy; Prognostication; Telomerase; Telomere

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; BONE MARROW DEPRESSION; CANCER GROWTH; CHROMOSOME DISORDER; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE MODEL; FOLLICULAR LYMPHOMA; GENE REARRANGEMENT; GENETIC STABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REVIEW; T CELL LEUKEMIA; TELOMERE DYSFUNCTION; TELOMERE HOMEOSTASIS;

ACUTE DISEASE; BONE MARROW DISEASES; DISEASE PROGRESSION; GENOMIC INSTABILITY; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOMA, B-CELL; MULTIPLE MYELOMA; PROGNOSIS; TELOMERE; TELOMERE SHORTENING;

EID: 84857033739     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.09022.x     Document Type: Review

References (131)

1. d'Adda di Fagagna, F., Reaper, P.M., Clay-Farrace, L., Fiegler, H., Carr, P., Von Zglinicki, T., Saretzki, G., Carter, N.P. & Jackson, S.P. (2003) A DNA damage checkpoint response in telomere-initiated senescence. Nature, 426, 194-198.
2. Alter, B.P., Giri, N., Savage, S.A. & Rosenberg, P.S. (2009) Cancer in dyskeratosis congenita. Blood, 113, 6549-6557.
3. Andreasson, P., Johansson, B., Billstrom, R., Garwicz, S., Mitelman, F. & Hoglund, M. (1998) Fluorescence in situ hybridization analyses of hematologic malignancies reveal frequent cytogenetically unrecognized 12p rearrangements. Leukemia, 12, 390-400.
4. Artandi, S.E., Chang, S., Lee, S.L., Alson, S., Gottlieb, G.J., Chin, L. & DePinho, R.A. (2000) Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature, 406, 641-645.
5. Aubert, G., Hills, M. & Lansdorp, P.M. (2011) Telomere length measurement-Caveats and a critical assessment of the available technologies and tools. Mutation Research, DOI:
6. Augereau, A., T'Kint de Roodenbeke, C., Simonet, T., Bauwens, S., Horard, B., Callanan, M., Leroux, D., Jallades, L., Salles, G., Gilson, E. & Poncet, D. (2011) Telomeric damage in early stage of chronic lymphocytic leukemia correlates with shelterin dysregulation. Blood, 118, 1316-1322.
7. Austen, B., Skowronska, A., Baker, C., Powell, J.E., Gardiner, A., Oscier, D., Majid, A., Dyer, M., Siebert, R., Taylor, A.M., Moss, P.A. & Stankovic, T. (2007) Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. Journal of Clinical Oncology, 25, 5448-5457.
8. Aviv, A., Hunt, S.C., Lin, J., Cao, X., Kimura, M. & Blackburn, E. (2011) Impartial comparative analysis of measurement of leukocyte telomere length/DNA content by Southern blots and qPCR. Nucleic Acids Research, 39, e134.
9. Baird, D.M. (2005) New developments in telomere length analysis. Experimental Gerontology, 40, 363-368.
10. Baird, D.M. (2008a) Mechanisms of telomeric instability. Cytogenetic and Genome Research, 122, 308-314.
11. Baird, D.M. (2008b) Telomere dynamics in human cells. Biochimie, 90, 116-121.
12. Baird, D.M. (2010) Variation at the TERT locus and predisposition for cancer. Expert Reviews in Molecular Medicine, 12, e16.
13. Baird, D.M., Rowson, J., Wynford-Thomas, D. & Kipling, D. (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. Nature Genetics, 33, 203-207.
14. Baumann, P. & Cech, T.R. (2000) Protection of telomeres by the Ku protein in fission yeast. Molecular Biology of the Cell, 11, 3265-3275.
15. Bechter, O.E., Eisterer, W., Pall, G., Hilbe, W., Kuhr, T. & Thaler, J. (1998) Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Research, 58, 4918-4922.
16. Bellon, M., Datta, A., Brown, M., Pouliquen, J.-F., Couppie, P., Kazanji, M. & Nicot, C. (2006) Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patents with adult T-cell leukemia. International Journal of Cancer, 119, 2090-2097.
17. Borssen, M., Cullman, I., Noren-Nystrom, U., Sundstrom, C., Porwit, A., Forestier, E. & Roos, G. (2011) hTERT promoter methylation and telomere length in childhood acute lymphoblastic leukemia-associations with immunophenotype and cytogenetic subgroup. Experimental Hematology, 39, 1144-1151.
18. Boultwood, J., Fidler, C., Shepherd, P., Watkins, F., Snowball, J., Haynes, S., Kusec, R., Gaiger, A., Littlewood, T.J., Peniket, A.J. & Wainscoat, J.S. (1999) Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia. American Journal of Hematology, 61, 5-9.
19. Boultwood, J., Peniket, A., Watkins, F., Shepherd, P., McGale, P., Richards, S., Fidler, C., Littlewood, T.J. & Wainscoat, J.S. (2000) Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase. Blood, 96, 358-361.
20. Brennan, S.K., Wang, Q., Tressler, R., Harley, C., Go, N., Bassett, E., Huff, C.A., Jones, R.J. & Matsui, W. (2010) Telomerase inhibition targets clonogenic multiple myeloma cells through telomere length-dependent and independent mechanisms. PLoS ONE, 5, e12487.
21. Britt-Compton, B., Rowson, J., Locke, M., Mackenzie, I., Kipling, D. & Baird, D.M. (2006) Structural stability and chromosome-specific telomere length is governed by cis-acting determinants in humans. Human Molecular Genetics, 15, 725-733.
22. Britt-Compton, B., Capper, R., Rowson, J. & Baird, D.M. (2009) Short telomeres are preferentially elongated by telomerase in human cells. FEBS Letters, 583, 3076-3080.
23. Britt-Compton, B., Lin, T.T., Ahmed, G., Weston, V., Jones, R.E., Fegan, C., Oscier, D.G., Stankovic, T., Pepper, C. & Baird, D.M. (2011) Extreme telomere erosion in ATM-mutated and 11q-deleted CLL patients is independent of disease stage. Leukemia, DOI:
24. Broccoli, D., Young, J.W. & de Lange, T. (1995) Telomerase activity in normal and malignant hematopoietic cells. Proceedings of the National Academy of Sciences of the United States of America, 92, 9082-9086.
25. Brugat, T., Gault, N., Baccelli, I., Maes, J., Roborel de Climens, A., Nguyen-Khac, F., Davi, F., Merle-Beral, H., Gilson, E., Goodhardt, M. & Delic, J. (2009) Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. Leukemia, 24, 246-251.
26. Brugat, T., Nguyen-Khac, F., Grelier, A., Merle-Beral, H. & Delic, J. (2010) Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. Blood, 116, 239-249.
27. Brummendorf, T.H., Holyoake, T.L., Rufer, N., Barnett, M.J., Schulzer, M., Eaves, C.J., Eaves, A.C. & Lansdorp, P.M. (2000) Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood, 95, 1883-1890.
28. Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S. & Reddel, R.R. (1995) Telomere elongation in immortal human cells without detectable telomerase activity. EMBO Journal, 14, 4240-4248.
29. Bryan, T.M., Englezou, A., Dalla-Pozza, L., Dunham, M.A. & Reddel, R.R. (1997) Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nature Medicine, 3, 1271-1274.
30. Calado, R.T., Regal, J.A., Hills, M., Yewdell, W.T., Dalmazzo, L.F., Zago, M.A., Lansdorp, P.M., Hogge, D., Chanock, S.J., Estey, E.H., Falcao, R.P. & Young, N.S. (2009) Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 106, 1187-1192.
31. Campbell, L.J., Fidler, C., Eagleton, H., Peniket, A., Kusec, R., Gal, S., Littlewood, T.J., Wainscoat, J.S. & Boultwood, J. (2006) hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia. Leukemia, 20, 671-679.
32. Campisi, J. (2003) Cancer and ageing: rival demons? Nature Reviews Cancer, 3, 339-349.
33. Capper, R., Britt-Compton, B., Tankimanova, M., Rowson, J., Letsolo, B., Man, S., Haughton, M. & Baird, D.M. (2007) The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes & Development, 21, 2495-2508.
34. Capraro, V., Zane, L., Poncet, D., Perol, D., Galia, P., Preudhomme, C., Bonnefoy-Berard, N., Gilson, E., Thomas, X., El-Hamri, M., Chelghoun, Y., Michallet, M., Wattel, E., Mortreux, F. & Sibon, D. (2011) Telomere deregulations possess cytogenetic, phenotype, and prognostic specificities in acute leukemias. Experimental Hematology, 39, 195-202 e192.
35. Chakraborty, S., Sun, C.L., Francisco, L., Sabado, M., Li, L., Chang, K.L., Forman, S., Bhatia, S. & Bhatia, R. (2009) Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. Journal of Clinical Oncology, 27, 791-798.
36. Chiu, C.P., Dragowska, W., Kim, N.W., Vaziri, H., Yui, J., Thomas, T.E., Harley, C.B. & Lansdorp, P.M. (1996) Differential expression of telomerase activity in hematopoietic progenitors from adult human bone marrow. Stem Cells, 14, 239-248.
37. Christensen, K., Thinggaard, M., McGue, M., Rexbye, H., Hjelmborg, J.V., Aviv, A., Gunn, D., van der Ouderaa, F. & Vaupel, J.W. (2009) Perceived age as clinically useful biomarker of ageing: cohort study. BMJ, 339, b5262.
38. Cohen, S.B., Graham, M.E., Lovrecz, G.O., Bache, N., Robinson, P.J. & Reddel, R.R. (2007) Protein composition of catalytically active human telomerase from immortal cells. Science, 315, 1850-1853.
39. Cottliar, A., Pedrazzini, E., Corrado, C., Engelberger, M.I., Narbaitz, M. & Slavutsky, I. (2003) Telomere shortening in patients with plasma cell disorders. European Journal of Haematology, 71, 334-340.
40. Cottliar, A.S., Panero, J., Pedrazzini, E., Noriega, M.F., Narbaitz, M., Rodriguez, A. & Slavutsky, I. (2009) Analysis of telomere length in mantle cell lymphoma. European Journal of Haematology, 83, 433-438.
41. Counter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider, C.W., Harley, C.B. & Bacchetti, S. (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO Journal, 11, 1921-1929.
42. Damle, R.N., Batliwalla, F.M., Ghiotto, F., Valetto, A., Albesiano, E., Sison, C., Allen, S.L., Kolitz, J., Vinciguerra, V.P., Kudalkar, P., Wasil, T., Rai, K.R., Ferrarini, M., Gregersen, P.K. & Chiorazzi, N. (2004) Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. Blood, 103, 375-382.
43. Deininger, M., Buchdunger, E. & Druker, B.J. (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105, 2640-2653.
44. Drummond, M.W., Lennard, A., Brummendrof, T.H. & Holyoake, T.L. (2004) Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid. Leukemia & Lymphoma, 45, 1775-1781.
45. Ely, S.A., Chadburn, A., Dayton, C.M., Cesarman, E. & Knowles, D.M. (2000) Telomerase activity in B-cell non-Hodgkin lymphoma. Cancer, 89, 445-452.
46. Engelhardt, M., Mackenzie, K., Drullinsky, P., Silver, R.T. & Moore, M.A. (2000) Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer Research, 60, 610-617.
47. Ghaffari, S.H., Shayan-Asl, N., Jamialahmadi, A.H., Alimoghaddam, K. & Ghavamzadeh, A. (2008) Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Annals of Oncology, 19, 1927-1934.
48. Grabowski, P., Hultdin, M., Karlsson, K., Tobin, G., Aleskog, A., Thunberg, U., Laurell, A., Sundstrom, C., Rosenquist, R. & Roos, G. (2005) Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood, 105, 4807-4812.
49. Greider, C.W. & Blackburn, E.H. (1985) Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell, 43, 405-413.
50. Gross, M., Mkrtchyan, H., Glaser, M., Fricke, H.J., Hoffken, K., Heller, A., Weise, A. & Liehr, T. (2009) Delineation of yet unknown cryptic subtelomere aberrations in 50% of acute myeloid leukemia with normal GTG-banding karyotype. International Journal of Oncology, 34, 417-423.
51. Gurkan, E., Tanriverdi, K. & Baslamisli, F. (2005) Telomerase activity in myelodysplastic syndromes. Leukemia Research, 29, 1131-1139.
52. Harada, K., Kurisu, K., Arita, K., Sadatomo, T., Tahara, H., Tahara, E., Ide, T. & Uozumi, T. (1999) Telomerase activity in central nervous system malignant lymphoma. Cancer, 86, 1050-1055.
53. Harley, C.B., Futcher, A.B. & Greider, C.W. (1990) Telomeres shorten during ageing of human fibroblasts. Nature, 345, 458-460.
54. Hartmann, U., Brummendorf, T.H., Balabanov, S., Thiede, C., Illme, T. & Schaich, M. (2005) Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica, 90, 307-316.
55. Heacock, M., Spangler, E., Riha, K., Puizina, J. & Shippen, D.E. (2004) Molecular analysis of telomere fusions in Arabidopsis: multiple pathways for chromosome end-joining. EMBO Journal, 23, 2304-2313.
56. Hills, M. & Lansdorp, P.M. (2009) Short telomeres resulting from heritable mutations in the telomerase reverse transcriptase gene predispose for a variety of malignancies. Annals of the New York Academy of Sciences, 1176, 178-190.
57. Hultdin, M., Rosenquist, R., Thunberg, U., Tobin, G., Norrback, K.F., Johnson, A., Sundstrom, C. & Roos, G. (2003) Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. British Journal of Cancer, 88, 593-598.
58. Kim, N.W., Piatyszek, M.A., Prowse, K.R., Harley, C.B., West, M.D., Ho, P.L., Coviello, G.M., Wright, W.E., Weinrich, S.L. & Shay, J.W. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011-2015.
59. Kimura, M., Hjelmborg, J.V., Gardner, J.P., Bathum, L., Brimacombe, M., Lu, X., Christiansen, L., Vaupel, J.W., Aviv, A. & Christensen, K. (2008) Telomere length and mortality: a study of leukocytes in elderly Danish twins. American Journal of Epidemiology, 167, 799-806.
60. Kirwan, M., Vulliamy, T., Marrone, A., Walne, A.J., Beswick, R., Hillmen, P., Kelly, R., Stewart, A., Bowen, D., Schonland, S.O., Whittle, A.M., McVerry, A., Gilleece, M. & Dokal, I. (2009) Defining the pathogenic role of telomerase mutations in myelodysplastic syndrome and acute myeloid leukemia. Human Mutation, 30, 1567-1573.
61. Klapper, W., Krams, M., Qian, W., Janssen, D. & Parwaresch, R. (2003) Telomerase activity in B-cell non-Hodgkin lymphomas is regulated by hTERT transcription and correlated with telomere-binding protein expression but uncoupled from proliferation. British Journal of Cancer, 89, 713-719.
62. Klaus, M., Haferlach, T., Schnittger, S., Kern, W., Hiddemann, W. & Schoch, C. (2004) Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 155, 47-56.
63. Knight, S.J. & Flint, J. (2000) Perfect endings: a review of subtelomeric probes and their use in clinical diagnosis. Journal of Medical Genetics, 37, 401-409.
64. Kolquist, K.A., Ellisen, L.W., Counter, C.M., Meyerson, M., Tan, L.K., Weinberg, R.A., Haber, D.A. & Gerald, W.L. (1998) Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genetics, 19, 182-186.
65. Kubuki, Y., Suzuki, M., Sasaki, H., Tayama, T., Yamashita, K., Maeda, K., Ido, A., Matsuoka, H., Okayama, A., Nakanishi, T. & Tsubouchi, H. (2005) Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leukemia & Lymphoma, 46, 393-399.
66. Ladetto, M., Compagno, M., Ricca, I., Pagano, M., Rocci, A., Astolfi, M., Drandi, D., di Celle, P.F., Dell'Aquila, M., Mantoan, B., Vallet, S., Pagliano, G., De Marco, F., Francese, R., Santo, L., Cuttica, A., Marinone, C., Boccadoro, M. & Tarella, C. (2004) Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood, 103, 4644-4649.
67. de Lange, T. (2005) Shelterin: the protein complex that shapes and safeguards human telomeres. Genes & Development, 19, 2100-2110.
68. Letsolo, B.T., Rowson, J. & Baird, D.M. (2010) Fusion of short telomeres in human cells is characterised by extensive deletion and microhomology and can result in complex rearrangements. Nucleic Acids Research, 38, 1841-1852.
69. Levy, M.Z., Allsopp, R.C., Futcher, A.B., Greider, C.W. & Harley, C.B. (1992) Telomere end-replication problem and cell aging. Journal of Molecular Biology, 225, 951-960.
70. Lin, T.T., Hewamana, S., Ward, R., Taylor, H., Payne, T., Pratt, G., Baird, D., Fegan, C. & Pepper, C. (2008) Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient. British Journal of Haematology, 142, 595-605.
71. Lin, T.T., Letsolo, B.T., Jones, R.E., Rowson, J., Pratt, G., Hewamana, S., Fegan, C., Pepper, C. & Baird, D.M. (2010) Telomere dysfunction and fusion during the progression of chronic lymphocytic leukaemia: evidence for a telomere crisis. Blood, 116, 1899-1907.
72. MacNamara, B., Wang, W., Chen, Z., Hou, M., Mazur, J., Gruber, A. & Porwit-MacDonald, A. (2001) Telomerase activity in relation to pro- and anti-apoptotic protein expression in high grade non-Hodgkin's lymphomas. Haematologica, 86, 386-393.
73. Maser, R.S., Wong, K.K., Sahin, E., Xia, H., Naylor, M., Hedberg, H.M., Artandi, S.E. & DePinho, R.A. (2007) DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Molecular and Cellular Biology, 27, 2253-2265.
74. Miller, D., Reynolds, G.E., Mejia, R., Stark, J.M. & Murnane, J.P. (2011) Subtelomeric regions in mammalian cells are deficient in DNA double-strand break repair. DNA Repair, 10, 536-544.
75. Mitelman, F., Johansson, B., Mandahl, N. & Mertens, F. (1997) Clinical significance of cytogenetic findings in solid tumors. Cancer Genetics and Cytogenetics, 95, 1-8.
76. Mrozek, K., Heerema, N.A. & Bloomfield, C.D. (2004) Cytogenetics in acute leukemia. Blood Reviews, 18, 115-136.
77. Murnane, J.P. (2010) Telomere loss as a mechanism for chromosome instability in human cancer. Cancer Research, 70, 4255-4259.
78. Murnane, J.P. (2011) Telomere dysfunction and chromosome instability. Mutation Research, DOI:
79. Nagel, I., Szczepanowski, M., Martin-Subero, J.I., Harder, L., Akasaka, T., Ammerpohl, O., Callet-Bauchu, E., Gascoyne, R.D., Gesk, S., Horsman, D., Klapper, W., Majid, A., Martinez-Climent, J.A., Stilgenbauer, S., Tonnies, H., Dyer, M.J. & Siebert, R. (2010) Deregulation of the telomerase reverse transcriptase (TERT) gene by chromosomal translocations in B-cell malignancies. Blood, 116, 1317-1320.
80. Norrback, K.F., Dahlenborg, K., Carlsson, R. & Roos, G. (1996) Telomerase activation in normal B lymphocytes and non-Hodgkin's lymphomas. Blood, 88, 222-229.
81. Norrback, K.F., Enblad, G., Erlanson, M., Sundstrom, C. & Roos, G. (1998) Telomerase activity in Hodgkin's disease. Blood, 92, 567-573.
82. Ohyashiki, J.H., Ohyashiki, K., Iwama, H., Hayashi, S., Toyama, K. & Shay, J.W. (1997a) Clinical implications of telomerase activity levels in acute leukemia. Clinical Cancer Research, 3, 619-625.
83. Ohyashiki, K., Ohyashiki, J.H., Iwama, H., Hayashi, S., Shay, J.W. & Toyama, K. (1997b) Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression. Leukemia, 11, 190-194.
84. Ohyashiki, J.H., Iwama, H., Yahata, N., Ando, K., Hayashi, S., Shay, J.W. & Ohyashiki, K. (1999) Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. Clinical Cancer Research, 5, 1155-1160.
85. Ohyashiki, K., Iwama, H., Yahata, N., Tauchi, T., Kawakubo, K., Shimamoto, T. & Ohyashiki, J.H. (2001) Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leukaemia & Lymphoma, 42, 291-299.
86. Ohyashiki, J.H., Sashida, G., Tauchi, T. & Ohyashiki, K. (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene, 21, 680-687.
87. Olovnikov, A.M. (1971) [Principle of marginotomy in template synthesis of polynucleotides]. Doklady Akademii nauk SSSR, 201, 1496-1499.
88. Ouillette, P., Fossum, S., Parkin, B., Ding, L., Bockenstedt, P., Al-Zoubi, A., Shedden, K. & Malek, S.N. (2010) Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. Clinical Cancer Research, 16, 835-847.
89. Ouillette, P., Collins, R., Shakhan, S., Li, J., Li, C., Shedden, K. & Malek, S.N. (2011) The prognostic significance of various 13q14 deletions in chronic lymphocytic leukemia. Clinical Cancer Research, 17, 6778-6790.
90. Pennaneach, V., Putnam, C.D. & Kolodner, R.D. (2006) Chromosome healing by de novo telomere addition in Saccharomyces cerevisiae. Molecular Microbiology, 59, 1357-1368.
91. Pepper, C. & Baird, D.M. (2010) Shortened telomeres: a driving force behind leukemia? Future Oncology, 6, 1681-1686.
92. Poncet, D., Belleville, A., T'Kint de Roodenbeke, C., Roborel de Climens, A., Ben Simon, E., Merle-Beral, H., Callet-Bauchu, E., Salles, G., Sabatier, L., Delic, J. & Gilson, E. (2007) Changes in the expression of telomere maintenance genes suggest global telomere dysfunction in B chronic lymphocytic leukemia. Blood, 111, 2388-2391.
93. Remes, K., Norrback, K.F., Rosenquist, R., Mehle, C., Lindh, J. & Roos, G. (2000) Telomere length and telomerase activity in malignant lymphomas at diagnosis and relapse. British Journal of Cancer, 82, 601-607.
94. Ricca, I., Rocci, A., Drandi, D., Francese, R., Compagno, M., Lobetti Bodoni, C., De Marco, F., Astolfi, M., Monitillo, L., Vallet, S., Calvi, R., Ficara, F., Omede, P., Rosato, R., Gallamini, A., Marinone, C., Bergui, L., Boccadoro, M., Tarella, C. & Ladetto, M. (2007) Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. Leukemia, 21, 697-705.
95. Rigolin, G.M., Porta, M.D., Ciccone, M., Bugli, A.M., Bragotti, L.Z., Mauro, E., Fraulini, C., Rossi, A.R., Bardi, A., Cuneo, A. & Castoldi, G. (2004) In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34 cells. British Journal of Haematology, 126, 501-507.
96. Risio, M., Casorzo, L., Chiecchio, L., De Rosa, G. & Rossini, F.P. (2003) Deletions of 17p are associated with transition from early to advanced colorectal cancer. Cancer Genetics and Cytogenetics, 147, 44-49.
97. Roos, G., Krober, A., Grabowski, P., Kienle, D., Buhler, A., Dohner, H., Rosenquist, R. & Stilgenbauer, S. (2008) Short telomeres are associated with genetic complexity, high risk genomic aberrations, and short survival in chronic lymphocytic leukemia. Blood, 111, 2246-2252.
98. Rossi, D.J., Bryder, D., Seita, J., Nussenzweig, A., Hoeijmakers, J. & Weissman, I.L. (2007) Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature, 447, 725-729.
99. Rossi, D., Lobetti Bodoni, C., Genuardi, E., Monitillo, L., Drandi, D., Cerri, M., Deambrogi, C., Ricca, I., Rocci, A., Ferrero, S., Bernocco, E., Capello, D., De Paoli, L., Bergui, L., Boi, M., Omede, P., Massaia, M., Tarella, C., Passera, R., Boccadoro, M., Gaidano, G. & Ladetto, M. (2009) Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. Leukemia, 23, 1062-1072.
100. Roth, A., Durig, J., Himmelreich, H., Bug, S., Siebert, R., Duhrsen, U., Lansdorp, P.M. & Baerlocher, G.M. (2007) Short telomeres and high telomerase activity in T-cell prolymphocytic leukemia. Leukemia, 21, 2456-2462.
101. Rudolph, K.L., Chang, S., Lee, H.W., Blasco, M., Gottlieb, G.J., Greider, C. & DePinho, R.A. (1999) Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell, 96, 701-712.
102. Rudolph, K.L., Millard, M., Bosenberg, M.W. & DePinho, R.A. (2001) Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nature Genetics, 28, 155-159.
103. Sahin, E. & Depinho, R.A. (2010) Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature, 464, 520-528.
104. Savage, S.A. & Alter, B.P. (2008) The role of telomere biology in bone marrow failure and other disorders. Mechanisms of Ageing and Development, 129, 35-47.
105. Shammas, M.A., Koley, H., Bertheau, R.C., Neri, P., Fulciniti, M., Tassone, P., Blotta, S., Protopopov, A., Mitsiades, C., Batchu, R.B., Anderson, K.C., Chin, A., Gryaznov, S. & Munshi, N.C. (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia, 22, 1410-1418.
106. Shet, A.S., Jahagirdar, B.N. & Verfaillie, C.M. (2002) Chronic myelogenous leukemia: mechanisms underlying disease progression. Leukemia, 16, 1402-1411.
107. Shih, I.M., Zhou, W., Goodman, S.N., Lengauer, C., Kinzler, K.W. & Vogelstein, B. (2001) Evidence that genetic instability occurs at an early stage of colorectal tumorigenesis. Cancer Research, 61, 818-822.
108. Shiratsuchi, M., Muta, K., Abe, Y., Motomura, S., Taguchi, F., Takatsuki, H., Uike, N., Umemura, T., Nawata, H. & Nishimura, J. (2002) Clinical significance of telomerase activity in multiple myeloma. Cancer, 94, 2232-2238.
109. Sieglova, Z., Zilovcova, S., Cermak, J., Rihova, H., Brezinova, D., Dvorakova, R., Markova, M., Maaloufova, J., Sajdova, J., Brezinova, J., Zemanova, Z. & Michalova, K. (2004) Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis? Leukemia Research, 28, 1013-1021.
110. Swiggers, S.J., Kuijpers, M.A., de Cort, M.J., Beverloo, H.B. & Zijlmans, J.M. (2006) Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer, 45, 247-256.
111. Teixeira, M.T., Arneric, M., Sperisen, P. & Lingner, J. (2004) Telomere length homeostasis is achieved via a switch between telomerase- extendible and -nonextendible states. Cell, 117, 323-335.
112. Terrin, L., Trentin, L., Degan, M., Corradini, I., Bertorelle, R., Carli, P., Maschio, N., Bo, M.D., Noventa, F., Gattei, V., Semenzato, G. & De Rossi, A. (2007) Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. Leukemia, 21, 965-972.
113. Vaziri, H., Dragowska, W., Allsopp, R.C., Thomas, T.E., Harley, C.B. & Lansdorp, P.M. (1994) Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age. Proceedings of the National Academy of Sciences of the United States of America, 91, 9857-9860.
114. Verstovsek, S., Kantarjian, H., Manshouri, T., Cortes, J., Faderl, S., Giles, F.J., Keating, M. & Albitar, M. (2003) Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer, 97, 1248-1252.
115. Verstovsek, S., Giles, F.J., O'Brien, S., Faderl, S., Kantarjian, H.M., Keating, M.J. & Albitar, M. (2004) Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leukemia Research, 28, 707-711.
116. Vulliamy, T., Marrone, A., Dokal, I. & Mason, P.J. (2002) Association between aplastic anaemia and mutations in telomerase RNA. Lancet, 359, 2168-2170.
117. Vulliamy, T., Marrone, A., Szydlo, R., Walne, A., Mason, P.J. & Dokal, I. (2004) Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nature Genetics, 36, 447-449.
118. Vulliamy, T.J., Walne, A., Baskaradas, A., Mason, P.J., Marrone, A. & Dokal, I. (2005) Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells, Molecules, and Diseases, 34, 257-263.
119. Vulliamy, T., Beswick, R., Kirwan, M., Marrone, A., Digweed, M., Walne, A. & Dokal, I. (2008) Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proceedings of the National Academy of Sciences of the United States of America, 105, 8073-8078.
120. Walne, A.J., Vulliamy, T., Beswick, R., Kirwan, M. & Dokal, I. (2008) TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood, 112, 3594-3600.
121. Walsh, S.H., Grabowski, P., Berglund, M., Thunberg, U., Thorselius, M., Tobin, G., Aleskog, A., Karlsson, K., Sundstrom, C., Laurell, A., Enblad, G., Rosenquist, R. & Roos, G. (2007) Telomere length and correlation with histopathogenesis in B-cell leukemias/lymphomas. European Journal of Haematology, 78, 283-289.
122. Wang, Y., Fang, M., Sun, X. & Sun, J. (2010) Telomerase activity and telomere length in acute leukemia: correlations with disease progression, subtypes and overall survival. International Journal of Laboratory Hematology, 32, 230-238.
123. Weng, N.P., Granger, L. & Hodes, R.J. (1997) Telomere lengthening and telomerase activation during human B cell differentiation. Proceedings of the National Academy of Sciences of the United States of America, 94, 10827-10832.
124. Wilkie, A.O., Lamb, J., Harris, P.C., Finney, R.D. & Higgs, D.R. (1990) A truncated human chromosome 16 associated with alpha thalassaemia is stabilized by addition of telomeric repeat (TTAGGG)n. Nature, 346, 868-871.
125. Wright, W.E. & Shay, J.W. (1992) The two-stage mechanism controlling cellular senescence and immortalization. Experimental Gerontology, 27, 383-389.
126. Wright, W.E., Tesmer, V.M., Huffman, K.E., Levene, S.D. & Shay, J.W. (1997) Normal human chromosomes have long G-rich telomeric overhangs at one end. Genes & Development, 11, 2801-2809.
127. Wu, K.J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J. & Dalla-Favera, R. (1999) Direct activation of TERT transcription by c-MYC. Nature Genetics, 21, 220-224.
128. Wu, K.D., Orme, L.M., Shaughnessy, Jr, J., Jacobson, J., Barlogie, B. & Moore, M.A. (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood, 101, 4982-4989.
129. Xu, D., Gruber, A., Peterson, C. & Pisa, P. (1998) Telomerase activity and the expression of telomerase components in acute myelogenous leukaemia. British Journal of Haematology, 102, 1367-1375.
130. Yamaguchi, H., Baerlocher, G.M., Lansdorp, P.M., Chanock, S.J., Nunez, O., Sloand, E. & Young, N.S. (2003) Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood, 102, 916-918.
131. Yamaguchi, H., Calado, R.T., Ly, H., Kajigaya, S., Baerlocher, G.M., Chanock, S.J., Lansdorp, P.M. & Young, N.S. (2005) Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. New England Journal of Medicine, 352, 1413-1424.